Sesen Bio (SESN) Gets a Buy Rating from Canaccord Genuity

By Ryan Adsit

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Sesen Bio (SESNResearch Report), with a price target of $5.00. The company’s shares closed last Monday at $1.06.

According to, Newman is a 5-star analyst with an average return of 18.1% and a 45.0% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Atara Biotherapeutics, and Allogene Therapeutics.

Sesen Bio has an analyst consensus of Moderate Buy, with a price target consensus of $3.63.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.54 and a one-year low of $0.37. Currently, Sesen Bio has an average volume of 1.38M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.